Bischoff, P., Reck, M., Overbeck, T., Christopoulos, P., Röper, J., Janning, M., . . . Thomas, M. (2024). Outcome of first-line treatment with pembrolizumab according to KRAS/TP53 mutational status for nonsquamous programmed death-ligand 1-High (≥50%) NSCLC in the German national network genomic medicine lung cancer. Journal of thoracic oncology, 19(5), . https://doi.org/10.1016/j.jtho.2023.12.015
Chicago-Zitierstil (17. Ausg.)Bischoff, Philip, Martin Reck, Tobias Overbeck, Petros Christopoulos, Julia Röper, Melanie Janning, Albrecht Stenzinger, Frank Griesinger, und Michael Thomas. "Outcome of First-line Treatment with Pembrolizumab According to KRAS/TP53 Mutational Status for Nonsquamous Programmed Death-ligand 1-High (≥50%) NSCLC in the German National Network Genomic Medicine Lung Cancer." Journal of Thoracic Oncology 19, no. 5 (2024). https://doi.org/10.1016/j.jtho.2023.12.015.
MLA-Zitierstil (9. Ausg.)Bischoff, Philip, et al. "Outcome of First-line Treatment with Pembrolizumab According to KRAS/TP53 Mutational Status for Nonsquamous Programmed Death-ligand 1-High (≥50%) NSCLC in the German National Network Genomic Medicine Lung Cancer." Journal of Thoracic Oncology, vol. 19, no. 5, 2024, https://doi.org/10.1016/j.jtho.2023.12.015.